MedTrace Logo

Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients

NCT02117518 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2014-04-23

No results posted yet for this study

Summary

It is well established that CD8 and CD4 T cells reactive against defined islet antigens are associated with initiation and progression of Type 1 Diabetes (T1D). In previous work, we have demonstrated that it is possible to redirect T cells against pathogenic T cells via chimeric peptide/MHC/CD3-zeta receptors in a peptide-specific manner and to prevent, or inhibit diabetes in NOD mice. In this study we intend to extend this approach to T cells of T1D patients. Working hypothesis: Beta cell-reactive CD8 T cells of human T1D patients can be immuno-targeted by their own gene-modified cytotoxic T lymphocytes (CTLs). Aims: Our major aim is to demonstrate, in a set of ex-vivo experiments, such immunotargeting with T cells derived from T1D patients at the Ziv Medical Center. To this end we will stimulate and expand autoreactive CD8 cells in blood samples of T1D patients and target them, ex-vivo, with genetically-reprogrammed CTLs which are present in the same blood samples.

Conditions

  • Type I Diabetes

Interventions

OTHER

blood drawing

Sponsors & Collaborators

  • Migal Galilee Research Institute

    lead OTHER

  • Ziv Medical Center

    collaborator OTHER

Principal Investigators

  • Gideon Gross, PhD · Migal Galilee Research Institute

  • Orna Gottfried, MD · Ziv Medical Center

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-12-31
Completion
2016-05-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02117518 on ClinicalTrials.gov